Prevalence of Iron Deficiency in Heart and Kidney Allograft Recipients

Przybyłowski, Piotr; Małyszko, Jolanta; Głowińska, Irena; Kozlowska, S.; Myśliwiec, M

doi:10.1016/j.transproceed.2011.08.083

Cited by 18 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TSAT and serum ferritin level are used as iron metabolism markers for grafts as in CKD patients, although their effectiveness in an inflammatory environment due to infections and rejection episodes is questioned [274,275]. One report showed that there was no significant difference between the efficacy of oral and intravenous iron supplementation for PTA patients [276].…”

Section: Rationalementioning

confidence: 99%

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Yamamoto¹,

et al. 2017

View full text Add to dashboard Cite

Section: Rationalementioning

confidence: 99%

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Yamamoto¹,

et al. 2017

View full text Add to dashboard Cite

“…80 In 105 heart transplantation recipients, iron deficiency was present in 39% after around 8 years of follow-up. 81 Iron administration in cardiac transplantation is a double-edged sword. Animal experiments in several organ-transplantation models have shown that after cardiac death of the donor, reduction of chelatable iron by the use of deferoxamine helps to reduce ischaemia-reperfusion injury, prolonging graft viability and function.…”

Section: Iron In Heart Transplantationmentioning

confidence: 99%

Iron deficiency and cardiovascular disease

Haehling

Jankowska

Veldhuisen³

et al. 2015

Nat Rev Cardiol

228

147

View full text Add to dashboard Cite

Iron deficiency affects up to one-third of the world's population, and is particularly common in elderly individuals and those with certain chronic diseases. Iron excess can be detrimental in cardiovascular illness, and research has now also brought anaemia and iron deficiency into the focus of cardiovascular medicine. Data indicate that iron deficiency has detrimental effects in patients with coronary artery disease, heart failure (HF), and pulmonary hypertension, and possibly in patients undergoing cardiac surgery. Around one-third of all patients with HF, and more than one-half of patients with pulmonary hypertension, are affected by iron deficiency. Patients with HF and iron deficiency have shown symptomatic improvements from intravenous iron administration, and some evidence suggests that these improvements occur irrespective of the presence of anaemia. Improved exercise capacity has been demonstrated after iron administration in patients with pulmonary hypertension. However, to avoid iron overload and T-cell activation, it seems that recipients of cardiac transplantations should not be treated with intravenous iron preparations.

show abstract

“…The main factors include inadequate production of erythropoietin, shortened erythrocyte survival, blood loss, iron and other nutritional deficiencies, hemolysis, and the uremic milieu [4]. Successful kidney transplantation results in correction of the anemia although up to one-third of the patients continue to be anemic after transplantation [5]. The anemia is very often associated with kidney dysfunction.…”

Section: Introductionmentioning

confidence: 99%

GDF15 Is Related to Anemia and Hepcidin in Kidney Allograft Recipients

et al. 2013

View full text Add to dashboard Cite

Anemia is more prevalent in renal transplant recipients than in GFR-matched chronic kidney disease patients. Hepcidin is a small defensin-like peptide whose production by hepatocytes is modulated in response to anemia, hypoxia or inflammation. Growth differentiation factor 15 (GDF15) was recently identified as a hepcidin-suppression factor that is expressed at high levels in patients with ineffective erythropoiesis. The aim of the study was to assess GDF15 levels with relation to iron parameters in 62 stable kidney allograft recipients maintained on triple immunosuppressive therapy. Methods: Complete blood count, urea, creatinine, and iron status were assessed by standard methods. We measured GDF15, hepcidin, hemojuvelin, IL-6 and NGAL with commercially available assays. Results: Mean levels of GDF15, NGAL, hepcidin and hemojuvelin were significantly higher in kidney allograft recipients when compared to the control group (p < 0.001 for all). GDF15 was significantly higher in patients with anemia according to the WHO definition when compared to their nonanemic counterparts (p < 0.05). GDF15 levels were not dependent on the type of immunosuppressive therapy. In univariate analysis GDF15 was related to kidney function (creatinine r = 0.39, p < 0.01, eGFR by MDRD r = -0.37, p < 0.01), urea (r = 0.39, p < 0.01), uric acid (r = 0.42, p < 0.01), hepcidin (r = -0.32, p < 0.01), IL-6 (r = 0.28, p < 0.05), hemoglobin (r = -0.32, p < 0.05), and NGAL (r = -0.35, p < 0.01). GDF15 was not related to serum iron, or ferritin. In multivariate analysis, hepcidin was found to be a predictor of GDF15. In conclusion, our preliminary data may suggest possible mutual relations between GDF15 and hepcidin in patients with kidney disease and that GDF15 might be involved in the pathogenesis of anemia in kidney allograft recipients. However, the role of inflammation should be also elucidated.

show abstract

Prevalence of Iron Deficiency in Heart and Kidney Allograft Recipients

Cited by 18 publications

References 16 publications

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

Iron deficiency and cardiovascular disease

GDF15 Is Related to Anemia and Hepcidin in Kidney Allograft Recipients

Contact Info

Product

Resources

About